8-K: MyMD Pharmaceuticals Secures $14 Million in Strategic Funding, Potential for $42 Million Total

MyMD Pharmaceuticals has secured an initial $14 million in a two-part funding round, with a potential for up to $42 million, from a new strategic investor and existing shareholders.

Summary

• MyMD Pharmaceuticals has secured $14 million in a two-part funding round, with a potential for up to $42 million.
• The initial $14 million includes $7 million from a new strategic investor, PharmaCyte Biotech, and $7 million from existing shareholders.
• The funding is intended to support the development of MYMD-1 in sarcopenia and the evaluation of other drug candidates.
• The Series G Preferred Stock financing round includes 8,950 shares of preferred stock with a stated value of $1,000 per share, convertible into common stock, and warrants to purchase up to 10,037,232 additional shares of common stock.
• The Series F-1 Preferred Stock financing round includes 5,050 shares of preferred stock with a stated value of $1,000 per share, convertible into common stock, and warrants to purchase up to 5,561,678 additional shares of common stock.
• The preferred stock in both rounds has an initial conversion price of $1.816 per share.
• The warrants in both rounds are immediately exercisable at an initial exercise price of $1.816 per share, with some expiring in five years and others in 18 months.
• The full conversion of the preferred stock and the full exercise of the warrants are subject to stockholder approval.
• The company expects to use the net proceeds from the Private Placements for general corporate purposes.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful funding round and the potential of the company's drug candidates. However, there are some risks and uncertainties associated with the transactions, which temper the overall sentiment.

Positives

• The funding provides capital to support the development of MYMD-1 and other drug candidates.
• The participation of a strategic investor, PharmaCyte Biotech, may bring additional expertise and resources.
• The participation of existing shareholders demonstrates confidence in the company's prospects.

Negatives

• The full conversion of the preferred stock and the full exercise of the warrants are subject to stockholder approval, which may introduce uncertainty.
• The conversion price of the preferred stock and the exercise price of the warrants are subject to adjustment, which may impact the value of the securities.

Risks

• The company's ability to settle conversions and make dividend make-whole payments using shares of Common Stock is subject to certain limitations.
• The Series G and Series F-1 Certificates of Designations include certain Triggering Events, including, among other things, the Companys failure to pay any amounts due to the holders of the Series G and Series F-1 Preferred Stock when due.
• The Company will be subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets, among other matters.

Future Outlook

The company expects to use the net proceeds from the Private Placements for general corporate purposes and to fund clinical studies of MYMD-1 in sarcopenia for the next two years.

Management Comments

• We are excited to welcome PharmaCyte as a new strategic investment partner in our continuing development of MYMD-1 in sarcopenia, as well as the evaluation of our other approved INDs in rheumatoid arthritis (RA) and Hashimotos thyroiditis.
• Likewise, we appreciate the participation of many of our valued existing shareholders who share strong conviction in our potentially groundbreaking drug candidates for combatting aging and treating autoimmune diseases.
• We believe that this capital infusion will fund us through our next clinical studies of MYMD-1 in sarcopenia for the next two years.

Industry Context

This announcement reflects a trend of biopharmaceutical companies seeking strategic investments to fund clinical trials and drug development. The involvement of PharmaCyte Biotech, a company focused on cellular therapies, suggests a potential synergy or collaboration in the future.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a common financing method for clinical-stage biopharmaceutical companies.
• The terms of the warrants, including the exercise price and expiration dates, are generally consistent with industry standards.
• The anti-dilution provisions in the preferred stock and warrants are designed to protect investors from future dilution.
• The requirement for stockholder approval for the full conversion of the preferred stock and exercise of the warrants is a standard practice for companies listed on the Nasdaq Capital Market.
• The 10% dividend rate on the preferred stock is relatively high, which may reflect the risk associated with investing in a clinical-stage company.

Stakeholder Impact

• Shareholders will experience potential dilution from the issuance of new shares.
• Employees may benefit from the increased funding for research and development.
• Customers may benefit from the development of new therapies.
• Creditors may be impacted by the new debt and equity financing.

Next Steps

• The company will close the private placements on or around May 22, 2024.
• The company will seek stockholder approval for the issuance of shares and an increase in authorized shares.
• The company will use the proceeds to fund clinical studies of MYMD-1 in sarcopenia.
• The company will file a registration statement for the resale of the Registrable Securities.

Key Dates

Keywords

private placement, convertible preferred stock, warrants, strategic investment, biopharmaceutical, MYMD-1, sarcopenia, autoimmune diseases, funding, capital raise